TRENTON, N.J. | FDA approves 1st nonopioid drug to ease withdrawal symptoms
TRENTON, N.J. (AP) — Federal regulators have approved the first nonopioid treatment to ease withdrawal symptoms from quitting addictive opioids.
The U.S. Food and Drug Administration expedited approval of Lucemyra (luc-eh-MEER’-eh) to help combat the U.S. opioid epidemic.
The tablet was approved Wednesday to treat adults for up to two weeks for common withdrawal symptoms like vomiting, diarrhea, muscle pain and agitation. It is not an addiction treatment but can be part of a longer-term plan.